RxDoctor Payments Data

Tracy Dziacky, PA

Physician Assistant · Lincoln, NENPI 1972257558

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 48 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$279
  • Actelion Pharmaceuticals US, Inc.$158
  • Astellas Pharma US Inc$153
  • Atricure, Inc.$139
  • Impulse Dynamics (USA) Inc.$132
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$96
  • plus $402 from 16 others

What the payments were for

  • Food & beverage$1,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 75th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$12,357
Medicare patients
100
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$50,609
XareltoRivaroxaban19$16,020
Metoprolol Succinate88$1,000
Ranolazine ErRanolazine15$872
Amlodipine Besylate66$713
Bisoprolol Fumarate26$551
Atorvastatin Calcium60$433
Ezetimibe22$423
Rosuvastatin Calcium35$361
Lisinopril28$349
Isosorbide Mononitrate ErIsosorbide Mononitrate24$345
Propranolol Hcl11$263
Metoprolol Tartrate62$229
ClopidogrelClopidogrel Bisulfate20$196
Losartan Potassium25$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$50,60949 claims
Johnson & JohnsonXarelto$23$16,02019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →